Loading...
•
Dec 31, 2020
PTC Therapeutics Q4 2020 Earnings Report
PTC Therapeutics reported its Q4 and full year 2020 financial results and provided a corporate update.
Key Takeaways
PTC Therapeutics reported total revenues of $118.9 million for the fourth quarter of 2020, compared to $96.5 million for the fourth quarter of 2019. Total revenues were $380.8 million for the full year 2020, compared to $307.0 million for the full year 2019. Net loss was $74.4 million for the fourth quarter of 2020, compared to net loss of $77.7 million for the fourth quarter of 2019.
Total revenues were $118.9 million for the fourth quarter of 2020.
Net product revenue for Q4 2020 was $107.3 million.
GAAP R&D expenses were $118 million for the fourth quarter of 2020.
Cash, cash equivalents, and marketable securities was $1.1 billion at December 31, 2020.
Revenue by Segment
Forward Guidance
PTC reaffirmed its full year 2021 guidance.
Positive Outlook
- PTC anticipates net product revenues for the DMD franchise for the full year 2021 to be between $355 and $375 million.
- PTC anticipates GAAP R&D and SG&A expense for the full year 2021 to be between $825 and $855 million.
- PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2021 to be between $725 and $755 million, excluding estimated non-cash, stock-based compensation expense of $100 million.
- Results from Phase 1 healthy volunteer study of PTC518 for Huntington disease program from the splicing platform are expected in the first half.
- Data from the healthy volunteer study for PTC857 are expected in the first half.
Challenges Ahead
- There are significant risks in the development, regulatory approval and commercialization of new products.
- There are no guarantees that any product will receive or maintain regulatory approval in any territory.
- There are no guarantees that any product will prove to be commercially successful, including Translarna, Emflaza, Evrysdi, Tegsedi, Waylivra or PTC-AADC.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...